首頁 > 市場調查報告書 > 醫療設備

體外診斷癌症癌症診斷

市場調查報告書

商品編碼

1735428

全球癌症診斷市場

Oncology Diagnostics: Global Markets

出版日期: 2025年05月23日 | 出版商:

BCC Research | 英文 192 Pages | 訂單完成後即時交付

價格

簡介目錄圖表

全球癌症診斷市場規模預計將從2024年的776億美元擴大到2029年的1,015億美元，2024年至2029年的年複合成長率為 5.5%。

診斷影像領域預計將從2024年的531億美元成長到2029年的678億美元，同期的年複合成長率為 5.0%。

次世代定序（NGS）領域預計將從2024年的28億美元成長到2029年的47億美元，同期預計年複合成長率為 10.7%。

本報告調查了全球癌症診斷市場，並提供了市場概況摘要、市場影響因素和市場機會分析、法律制度、新興技術和技術發展趨勢、市場規模趨勢和預測、各個細分市場和地區的詳細分析、競爭格局以及主要企業的概況。

關鍵要點
市場促進因素
癌症發生率增加
早期療育和預防性診斷篩檢的需求
伴隨診斷的應用範圍不斷擴大
全球老化
市場機會
擴大癌症篩檢
增強取得先進技術的管道
市場限制
複雜的償付政策
缺乏對癌症的認知
癌症診斷測試的費用
癌症診斷週轉時間
市場挑戰
專業技能人才短缺
複雜的樣品製備與處理

第4章監管情況

市場監管（主要國家）
美國
歐洲
日本
中國

第5章新興技術與發展

新興技術
人工智慧在癌症診斷的應用
多種癌症早期檢測（MCED）
治療診斷學
數位病理學與人工智慧整合
專利分析
關鍵要點

第6章癌症診斷市場

細分市場
全球市場洞察
依產品類型分類的市場
診斷影像
內視鏡設備
腫瘤生物標記檢測
切片檢查裝置
蘇木精和伊紅
免疫組織化學
原位雜合技術
聚合酵素鏈鎖反應
次世代定序
其他
市場區隔：依應用
乳癌
肺癌
大腸直腸癌
攝護腺癌
胃癌
其他
市場區隔：依最終用戶
醫院、癌症中心、診所
診斷影像與參考實驗室
其他
地理分佈
市場區隔：依地區
關鍵要點
北美洲
歐洲
亞太地區
南美洲
中東和非洲

第7章競爭訊息

企業市場占有率分析
策略舉措

第8章癌症診斷市場的永續性：ESG 視角

ESG：簡介
ESG績效分析
環境績效
社會績效
管治績效
BCC的結語

第9章附錄

調查方法
參考
簡稱
公司簡介
ABBOTT
AGILENT TECHNOLOGIES INC.
BD
BIOMERIEUX
BIO-RAD LABORATORIES INC.
DANAHER CORP.
F. HOFFMANN-LA ROCHE LTD.
GE HEALTHCARE
ILLUMINA INC.
KONINKLIJKE PHILIPS NV
MERCK KGAA
MYRIAD GENETICS INC.
QIAGEN
SIEMENS HEALTHINEERS AG
THERMO FISHER SCIENTIFIC INC.
ZYTOVISION GMBH
其他新興企業

簡介目錄圖表

Product Code: MDS046B

The global market for oncology diagnostics is estimated to increase from $77.6 billion in 2024 to reach $101.5 billion by 2029, at a compound annual growth rate (CAGR) of 5.5% from 2024 through 2029.

The diagnostic imaging market for oncology diagnostics is estimated to increase from $53.1 billion in 2024 to reach $67.8 billion by 2029, at a CAGR of 5.0% from 2024 through 2029.

The next-generation sequencing (NGS) market for oncology diagnostics is estimated to increase from $2.8 billion in 2024 to reach $4.7 billion by 2029, at a CAGR of 10.7% from 2024 through 2029.

Report Scope

This report analyzes the oncology diagnostics market and the competitive landscape. The profiles of several leading companies, including their revenues, product portfolios and recent activities are also examined. The report analyzes market dynamics, including drivers, limitations, challenges and opportunities, and discusses current and potential market size. The report will enable companies in the industry to make informed decisions about the production and licensing of goods and services.

The market is divided into the following segments: diagnostic imaging, tumor biomarker tests, endoscopy, biopsy, hematoxylin and eosin (H&E) staining, immunohistochemistry (IHC), in situ hybridization (ISH), polymerase chain reaction (PCR), next generation sequencing (NGS) and others (cytology, microarrays, exosomes, flow cytometry, sanger sequencing, pyrosequencing etc.). The market is segmented by application into breast cancer, lung cancer, colorectal cancer, prostate cancer, gastric cancer and other cancers (lip, oral/cavity, liver/gallbladder, pancreas, melanoma, kidney, bladder, brain, central nervous system, thyroid, Hodgkin lymphoma, non-Hodgkin lymphoma, multiple myeloma and leukemia). By end user, the market is segmented into hospitals/cancer centers/clinics, diagnostic imaging centers/reference laboratories, and other end users (physician offices, research, academic institutes, national cancer registries and contract research organizations).

Regional market analysis is provided for North America, Europe, Asia-Pacific, South America and Middle East and Africa. The report also provides country-level analyses of markets and market segments. North America comprises the U.S., Canada and Mexico, while South America includes Brazil, Argentina and the rest of South America. In Europe, major countries covered are Germany, France, the U.K., Italy and Spain, along with the rest of Europe, which includes Switzerland, Denmark, Norway, Poland, Belgium, Austria, the Netherlands, Sweden, Russia and others. The Asia-Pacific region consists of Japan, China and India, as well as the rest of Asia-Pacific (Australia, New Zealand, Taiwan, Singapore, Malaysia, Thailand, the Philippines, South Korea, Indonesia etc.), and the Middle East and Africa.

The base year for the study is 2023, 2024 is the estimated year, with projections through 2029, including compound annual growth rates (CAGRs) for the forecast period.

Report Includes

94 data tables and 59 additional tables
Analyses of global market trends for oncology diagnostics, with market revenue data from 2021 to 2024, forecasts and projected CAGRs through 2029
Estimates of the size and growth of the global market, and a corresponding market share analysis by product type, application, end user, and region
Facts and figures pertaining to the major market dynamics, opportunities and challenges, emerging technologies, regulations, and impacts of macroeconomic variables
Insights derived from the Porter's Five Forces model, as well as global supply chain and PESTLE analyses
Coverage of treatments in development for late- and early-stage oncolytic viruses, along with epidemiological information, data corresponding to cancer incidence and mortality trends
Evaluation of recent patent activity featuring key granted and published patents
Insights into oncology therapeutics research activity, emerging technologies, clinical trials and pipeline products
Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, and the ESG scores and practices of leading companies
Analysis of the industry structure, including companies' market shares and rankings, strategic alliances, M&A activity and a venture funding outlook
Company profiles of major players within the industry, including F. Hoffmann-La Roche Ltd., Danaher Corp., Agilent Technologies Inc., Siemens Healthineers AG, and GE HealthCare

Chapter 1 Executive Summary

Market Outlook
Scope of Report
Market Summary
Market Dynamics and Growth Factors
Emerging Technologies
Segmental Analysis
Regional Analysis
Strategic Initiatives
Conclusion

Chapter 2 Market Overview

Overview
Macroeconomic Factors Analysis
Impact of the U.S.-China Trade War
Porter's Five Forces Analysis in the Oncology Market
Potential of New Entrants (Moderate to Low)
Bargaining Power of Suppliers (Moderate to High)
Bargaining Power of Buyers (Moderate to High)
Threat of Substitute Products or Services (Low)
Industry Rivalry (High)

Chapter 3 Market Dynamics

Key Takeaways
Market Drivers
Rising Incidence of Cancer Cases
Demand for Earlier Intervention and Preventive Diagnostic Screening
Growing Adoption of Companion Diagnostics
Increasing Aging Population Worldwide
Market Opportunities
Expanding Cancer Screening
Enhancing Access to Advanced Technologies
Market Restraints
Complex Reimbursement Policies
Lack of Cancer Awareness
Cost of Oncology Diagnostic Tests
Turnaround Time of Oncology Diagnostics
Market Challenges
Lack of Skilled Professionals
Complex Sample Preparation and Handling

Chapter 4 Regulatory Landscape

Market Regulations, by Top Country/Region
The U.S.
Europe
Japan
China

Chapter 5 Emerging Technologies and Developments

Emerging Technologies
AI in Oncology Diagnostics
Multi-Cancer Early Detection (MCED)
Theranostics
Digital Pathology and AI Integration
Patent Analysis
Key Takeaways

Chapter 6 Oncology Diagnostics Market

Segment Breakdown
Global Market Insights
Market Breakdown by Product Type
Diagnostics Imaging
Endoscopy Devices
Tumor Biomarker Tests
Biopsy Devices
Hematoxylin and Eosin
Immunohistochemistry
In situ Hybridization
Polymerase Chain Reaction
Next-Generation Sequencing
Others
Market Breakdown by Application
Breast Cancer
Lung Cancer
Colorectal Cancer
Prostate Cancer
Gastric Cancer
Other Applications
Market Breakdown by End User
Hospitals, Cancer Centers and Clinics
Diagnostic Imaging and Reference Laboratories
Others
Geographic Breakdown
Market Breakdown, by Region
Key Takeaways
North America
Europe
Asia-Pacific
South America
Middle East and Africa (MEA)

Chapter 7 Competitive Intelligence

Company Share Analysis
Strategic Initiatives

Chapter 8 Sustainability in the Market for Oncology Diagnostics: An ESG Perspective

Introduction to ESG
ESG Performance Analysis
Environmental Performance
Social Performance
Governance Performance
Concluding Remarks from BCC

Chapter 9 Appendix

Research Methodology
References
Abbreviations
Company Profiles
ABBOTT
AGILENT TECHNOLOGIES INC.
BD
BIOMERIEUX
BIO-RAD LABORATORIES INC.
DANAHER CORP.
F. HOFFMANN-LA ROCHE LTD.
GE HEALTHCARE
ILLUMINA INC.
KONINKLIJKE PHILIPS N.V.
MERCK KGAA
MYRIAD GENETICS INC.
QIAGEN
SIEMENS HEALTHINEERS AG
THERMO FISHER SCIENTIFIC INC.
ZYTOVISION GMBH
Other Emerging Players in the Oncology Diagnostics Market

簡介目錄圖表

List of Tables

Summary Table : Global Market for Oncology Diagnostics, by Product Type, Through 2029
Table 1 : Global Incidence of All Cancer Cases, by WHO Region, 2022-2045
Table 2 : Global Incidence of Cancer Cases, Both Sexes, by Cancer Type, 2022
Table 3 : Cancer Treatments Based on Specific Tests
Table 4 : Select FDA-Approved AI-Associated/Associable-Equipped Medical Devices
Table 5 : Selected Patent Grants in Oncology Diagnostics, 2023-2025
Table 6 : Global Oncology Diagnostics Market, by Product Type, Through 2029
Table 7 : Global Diagnostics Imaging Market, by Region, Through 2029
Table 8 : Global Endoscopy Market, by Region, Through 2029
Table 9 : Global Tumor Biomarker Tests Market, by Region, Through 2029
Table 10 : Global Biopsy Devices Market, by Region, Through 2029
Table 11 : Global H&E and Special Stains Diagnostics Market, by Region, Through 2029
Table 12 : Global IHC Oncology Diagnostics Market, by Region, Through 2029
Table 13 : Global ISH Oncology Diagnostics Market, by Region, Through 2029
Table 14 : Global PCR Oncology Diagnostics Market, by Region, Through 2029
Table 15 : Global NGS Oncology Diagnostics Market, by Region, Through 2029
Table 16 : Global Other Oncology Diagnostics Tests Market, by Region, Through 2029
Table 17 : Global Oncology Diagnostics Market, by Application, Through 2029
Table 18 : Global Breast Cancer Diagnostics Market, by Region, Through 2029
Table 19 : Global Lung Cancer Diagnostics Market, by Region, Through 2029
Table 20 : Global Colorectal Cancer Diagnostics Market, by Region, Through 2029
Table 21 : Global Prostate Cancer Diagnostics Market, by Region, Through 2029
Table 22 : Global Gastric Cancer Diagnostics Market, by Region, Through 2029
Table 23 : Global Oncology Diagnostics Market in Other Cancer Applications, by Region, Through 2029
Table 24 : Global Oncology Diagnostics Market, by End User, Through 2029
Table 25 : Global Oncology Diagnostics Market in Hospitals, Cancer Centers and Clinics, Through 2029
Table 26 : Global Oncology Diagnostics Market in Diagnostic Imaging and Reference Laboratories, Through 2029
Table 27 : Global Oncology Diagnostics Market in Other End Uses, Through 2029
Table 28 : Global Oncology Diagnostics Market, by Region, Through 2029
Table 29 : North American Oncology Diagnostics Market, by Country, Through 2029
Table 30 : U.S. Oncology Diagnostics Market, by Product Type, Through 2029
Table 31 : U.S. Oncology Diagnostics Market, by Application, Through 2029
Table 32 : U.S. Oncology Diagnostics Market, by End User, Through 2029
Table 33 : Canadian Oncology Diagnostics Market, by Product Type, Through 2029
Table 34 : Canadian Oncology Diagnostics Market, by Application, Through 2029
Table 35 : Canadian Oncology Diagnostics Market, by End User, Through 2029
Table 36 : Mexican Oncology Diagnostics Market, by Product Type, Through 2029
Table 37 : Mexican Oncology Diagnostics Market, by Application, Through 2029
Table 38 : Mexican Oncology Diagnostics Market, by End User, Through 2029
Table 39 : European Oncology Diagnostics Market, by Country, Through 2029
Table 40 : Cancer Incidence and Mortality Numbers in Germany, Both Sexes, 2022
Table 41 : German Oncology Diagnostics Market, by Product Type, Through 2029
Table 42 : German Oncology Diagnostics Market, by Application, Through 2029
Table 43 : German Oncology Diagnostics Market, by End User, Through 2029
Table 44 : Cancer Incidence and Mortality Numbers in France, Both Sexes, 2022
Table 45 : French Oncology Diagnostics Market, by Product Type, Through 2029
Table 46 : French Oncology Diagnostics Market, by Application, Through 2029
Table 47 : French Oncology Diagnostics Market, by End User, Through 2029
Table 48 : New Cases of Cancer Diagnosed Each Year in the U.K., 2021
Table 49 : The U.K. Oncology Diagnostics Market, by Product Type, Through 2029
Table 50 : The U.K. Oncology Diagnostics Market, by Application, Through 2029
Table 51 : The U.K. Oncology Diagnostics Market, by End User, Through 2029
Table 52 : Cancer Incidence and Mortality Numbers in Italy, Both Sexes, 2022
Table 53 : Italian Oncology Diagnostics Market, by Product Type, Through 2029
Table 54 : Italian Oncology Diagnostics Market, by Application, Through 2029
Table 55 : Italian Oncology Diagnostics Market, by End User, Through 2029
Table 56 : Cancer Incidence and Mortality Numbers in Spain, Both Sexes, 2022
Table 57 : Spanish Oncology Diagnostics Market, by Product Type, Through 2029
Table 58 : Spanish Oncology Diagnostics Market, by Application, Through 2029
Table 59 : Spanish Oncology Diagnostics Market, by End User, Through 2029
Table 60 : Rest of European Countries' Oncology Diagnostics Market, by Product Type, Through 2029
Table 61 : Rest of European Countries' Oncology Diagnostics Market, by Application, Through 2029
Table 62 : Rest of European Countries' Oncology Diagnostics Market, by End User, Through 2029
Table 63 : Asia-Pacific Oncology Diagnostics Market, by Country, Through 2029
Table 64 : Cancer Incidence and Mortality Numbers in China, Both Sexes, 2022
Table 65 : Chinese Oncology Diagnostics Market, by Product Type, Through 2029
Table 66 : Chinese Oncology Diagnostics Market, by Application, Through 2029
Table 67 : Chinese Oncology Diagnostics Market, by End User, Through 2029
Table 68 : Cancer Incidence and Mortality Numbers in Japan, Both Sexes, 2022
Table 69 : Japanese Oncology Diagnostics Market, by Product Type, Through 2029
Table 70 : Japanese Oncology Diagnostics Market, by Application, Through 2029
Table 71 : Japanese Oncology Diagnostics Market, by End User, Through 2029
Table 72 : Cancer Incidence and Mortality Numbers in India, Both Sexes, 2022
Table 73 : Indian Oncology Diagnostics Market, by Product Type, Through 2029
Table 74 : Indian Oncology Diagnostics Market, by Application, Through 2029
Table 75 : Indian Oncology Diagnostics Market, by End User, Through 2029
Table 76 : Rest of Asia-Pacific Oncology Diagnostics Market, by Product Type, Through 2029
Table 77 : Rest of Asia-Pacific Oncology Diagnostics Market, by Application, Through 2029
Table 78 : Rest of Asia-Pacific Oncology Diagnostics Market, by End User, Through 2029
Table 79 : South American Oncology Diagnostics Market, by Country, Through 2029
Table 80 : Brazilian Oncology Diagnostics Market, by Product Type, Through 2029
Table 81 : Brazilian Oncology Diagnostics Market, by Application, Through 2029
Table 82 : Brazilian Oncology Diagnostics Market, by End User, Through 2029
Table 83 : Argentine Oncology Diagnostics Market, by Product Type, Through 2029
Table 84 : Argentine Oncology Diagnostics Market, by Application, Through 2029
Table 85 : Argentine Oncology Diagnostics Market, by End User, Through 2029
Table 86 : Rest of South American Oncology Diagnostics Market, by Product Type, Through 2029
Table 87 : Rest of South American Oncology Diagnostics Market, by Application, Through 2029
Table 88 : Rest of South American Oncology Diagnostics Market, by End User, Through 2029
Table 89 : Middle East and African Oncology Diagnostics Market, by Product Type, Through 2029
Table 90 : Middle East and African Oncology Diagnostics Market, by Application, Through 2029
Table 91 : Middle East and African Oncology Diagnostics Market, by End User, Through 2029
Table 92 : Company Shares in the Oncology Diagnostics Market, 2023
Table 93 : ESG: Environmental Overview
Table 94 : ESG: Social Overview
Table 95 : ESG: Governance Overview
Table 96 : Abbreviations Used in this Report
Table 97 : Abbott: Company Snapshot
Table 98 : Abbott: Financial Performance, FY 2022 and 2023
Table 99 : Abbott: Product Portfolio
Table 100 : Agilent Technologies Inc.: Company Snapshot
Table 101 : Agilent Technologies Inc.: Financial Performance, FY 2023 and 2024
Table 102 : Agilent Technologies Inc.: Product Portfolio
Table 103 : Agilent Technologies Inc.: News/Key Developments, 2024
Table 104 : BD: Company Snapshot
Table 105 : BD: Financial Performance, FY 2023 and 2024
Table 106 : BD: Product Portfolio
Table 107 : bioMerieux: Company Snapshot
Table 108 : bioMerieux: Financial Performance, FY 2022 and 2023
Table 109 : bioMerieux: Product Portfolio
Table 110 : Bio-Rad Laboratories Inc.: Company Snapshot
Table 111 : Bio-Rad Laboratories Inc.: Financial Performance, FY 2023 and 2024
Table 112 : Bio-Rad Laboratories Inc.: Product Portfolio
Table 113 : Danaher Corp.: Company Snapshot
Table 114 : Danaher Corp.: Financial Performance, FY 2022 and 2023
Table 115 : Danaher Corp.: Product Portfolio
Table 116 : Danaher Corp.: News/Key Developments, 2023
Table 117 : F. Hoffmann-La Roche Ltd.: Company Snapshot
Table 118 : F. Hoffmann-La Roche Ltd.: Financial Performance, FY 2023 and 2024
Table 119 : F. Hoffmann-La Roche Ltd.: Product Portfolio
Table 120 : F. Hoffmann-La Roche Ltd.: News/Key Developments, 2024 and 2025
Table 121 : GE HealthCare: Company Snapshot
Table 122 : GE HealthCare: Financial Performance, FY 2023 and 2024
Table 123 : GE HealthCare: Product Portfolio
Table 124 : GE HealthCare: News/Key Developments, 2024
Table 125 : Illumina Inc.: Company Snapshot
Table 126 : Illumina Inc.: Financial Performance, FY 2023 and 2024
Table 127 : Illumina Inc.: Product Portfolio
Table 128 : Illumina Inc.: News/Key Developments, 2024
Table 129 : Koninklijke Philips N.V.: Company Snapshot
Table 130 : Koninklijke Philips N.V.: Financial Performance, FY 2023 and 2024
Table 131 : Koninklijke Philips N.V.: Product Portfolio
Table 132 : Merck KGaA: Company Snapshot
Table 133 : Merck KGaA: Financial Performance, FY 2022 and 2023
Table 134 : Merck KGaA: Product Portfolio
Table 135 : Myriad Genetics Inc.: Company Snapshot
Table 136 : Myriad Genetics Inc.: Financial Performance, FY 2022 and 2023
Table 137 : Myriad Genetics Inc.: Product Portfolio
Table 138 : Myriad Genetics Inc.: News/Key Developments, 2025
Table 139 : Qiagen: Company Snapshot
Table 140 : Qiagen: Financial Performance, FY 2022 and 2023
Table 141 : Qiagen: Product Portfolio
Table 142 : Siemens Healthineers AG: Company Snapshot
Table 143 : Siemens Healthineers AG: Financial Performance, FY 2023 and 2024
Table 144 : Siemens Healthineers AG: Product Portfolio
Table 145 : Siemens Healthineers AG: News/Key Developments, 2024
Table 146 : Thermo Fisher Scientific Inc.: Company Snapshot
Table 147 : Thermo Fisher Scientific Inc.: Financial Performance, FY 2022 and 2023
Table 148 : Thermo Fisher Scientific Inc.: Product Portfolio
Table 149 : Thermo Fisher Scientific Inc.: News/Key Developments, 2023
Table 150 : ZytoVision GmbH: Company Snapshot
Table 151 : ZytoVision GmbH: Product Portfolio
Table 152 : Emerging Startups in Oncology Diagnostics Market

List of Figures

Summary Figure : Global Market Shares of Oncology Diagnostics, by Product Type, 2023
Figure 1 : Porter's Five Forces Analysis of the Oncology Market
Figure 2 : Market Dynamics of Oncology Diagnostics
Figure 3 : Global Incidence Shares of All Cancer Cases, by Region, 2022
Figure 4 : Number of FDA-Approved Companion Diagnostic Devices, 1997-2024
Figure 5 : Emerging Trends and Technologies in Oncology Diagnostics
Figure 6 : Share of Global Market for Oncology Diagnostics, by Product Type, 2023
Figure 7 : Share of Global Market for Oncology Diagnostics, by Application, 2023
Figure 8 : Shares of Global Market for Oncology Diagnostics, by End User, 2023
Figure 9 : Share of Global Market for Oncology Diagnostics, by Region, 2023
Figure 10 : Share of North American Market for Oncology Diagnostics, by Country, 2023
Figure 11 : Share of European Market for Oncology Diagnostics, by Country, 2023
Figure 12 : Breast Cancer Screening Rates in Europe, by Country, 2012 vs. 2022
Figure 13 : Cervical Cancer Screening Rates in European Countries, 2022
Figure 14 : Colorectal Cancer Screening Rates in European Countries, 2022
Figure 15 : Current and Forecasted Cancer Prevalence in the U.K., 2020-2040
Figure 16 : Shares of Cancer Cases in Asia and Oceania, Both Sexes, by Cancer Type, 2022
Figure 17 : Shares of All Cancer Mortality Cases in Asia and Oceania, Both Sexes, by Cancer Type, 2022
Figure 18 : Share of Asia-Pacific Market for Oncology Diagnostics, by Country, 2023
Figure 19 : Share of South American Market for Oncology Diagnostics, by Country, 2023
Figure 20 : Share of the Global Market for Oncology Diagnostics, by Company, 2023
Figure 21 : ESG Pillars
Figure 22 : Advantages of ESG for Companies
Figure 23 : Abbott: Revenue Share, by Business Unit, FY 2023
Figure 24 : Abbott: Revenue Share, by Country/Region, FY 2023
Figure 25 : Agilent Technologies Inc.: Revenue Share, by Business Unit, FY 2024
Figure 26 : Agilent Technologies Inc.: Revenue Share, by Country/Region, FY 2024
Figure 27 : BD: Revenue Share, by Business Unit, FY 2024
Figure 28 : BD: Revenue Share, by Country/Region, FY 2024
Figure 29 : bioMerieux: Revenue Share, by Business Unit, FY 2023
Figure 30 : bioMerieux: Revenue Share, by Region, FY 2023
Figure 31 : Bio-Rad Laboratories Inc.: Revenue Share, by Business Unit, FY 2024
Figure 32 : Bio-Rad Laboratories Inc.: Revenue Share, by Country/Region, FY 2024
Figure 33 : Danaher Corp.: Revenue Share, by Business Unit, FY 2023
Figure 34 : Danaher Corp.: Revenue Share, by Country/Region, FY 2023
Figure 35 : F. Hoffmann-La Roche Ltd.: Revenue Share, by Business Unit, FY 2024
Figure 36 : F. Hoffmann-La Roche Ltd.: Revenue Share, by Business Unit, FY 2024
Figure 37 : GE HealthCare: Revenue Share, by Business Unit, FY 2024
Figure 38 : GE HealthCare: Revenue Share, by Country/Region, FY 2024
Figure 39 : Illumina Inc.: Revenue Share, by Business Unit, FY 2024
Figure 40 : Illumina Inc.: Revenue Share, by Country/Region, FY 2024
Figure 41 : Koninklijke Philips N.V.: Revenue Share, by Business Unit, FY 2024
Figure 42 : Koninklijke Philips N.V.: Revenue Share, by Country/Region, FY 2023
Figure 43 : Merck KGaA: Market Share, by Business Unit, 2023
Figure 44 : Merck KGaA: Revenue Share, by Country/Region, 2023
Figure 45 : Myriad Genetics Inc.: Revenue Share, by Business Unit, 2023
Figure 46 : Myriad Genetics Inc.: Revenue Share, by Country/Region, 2023
Figure 47 : Qiagen: Revenue Share, by Business Unit, FY 2023
Figure 48 : Qiagen: Revenue Share, by Country/Region, FY 2023
Figure 49 : Siemens Healthineers AG: Revenue Share, by Business Unit, FY 2024
Figure 50 : Siemens Healthineers AG: Revenue Share, by Country/Region, FY 2024
Figure 51 : Thermo Fisher Scientific Inc.: Revenue Share, by Business Unit, 2023
Figure 52 : Thermo Fisher Scientific Inc.: Revenue Share, by Country/Region, 2023